IP Library Granted Patent US 8,563,750
Granted Patent B2
US 8,563,750 · App. 13/214,559 · Granted Oct 22, 2013

Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylmino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,563,750
App. No.
13/214,559
Granted
Oct 22, 2013
Kind
B2
Abstract

Novel forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form XX, Form XXI, Form XXII, Form XXIII, Form XXIV, Form XXV, Form XXVI, Form XXVII, Form XXVIII, Form XXIX, and Form XXX, characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease.

Claims (6)

1. A Form XXVII atorvastatin calcium having an X-ray powder diffraction containing the following 2θ values measured using CuK a radiation: 3.9, 4.6, 7.1, 7.5, 9.6, 10.6, 11.8, 13.0, 15.3, and 18.7.

2. A Form XXVII atorvastatin calcium having an X-ray powder diffraction containing the following 2θ values measured using CuK a radiation: 3.9, 7.5, and 18.7, and a solid state 19 F nuclear magnetic resonance having the following chemical shifts expressed in parts per million: −112.2, −113.0, and −117.2.

3. A Form XXVII atorvastatin calcium having an X-ray powder diffraction containing the following 2θ values measured using CuK a radiation: 3.5, 3.9, 4.6, 7.1, 7.5, 7.9, 9.6, 9.9, 10.6, 11.8, 13.0, 15.3, 16.6, 17.2, 18.7, 22.6, 23.8, and 25.1.

4. A Form XXVII atorvastatin calcium having a solid state 13 C nuclear magnetic resonance having the following chemical shifts expressed in parts per million: 179.7, 166.0, 163.6, 161.7, 140.7, 133.8, 128.8, 122.4, 115.3, 72.5, 70.9, 66.6, 41.8, 27.3, and 22.0.

5. A Form XXVII atorvastatin calcium characterized by Raman spectroscopy having the following peaks expressed in cm −1 : 130, 288, 366, 512, 581, 618, 634, 736, 821, 858, 898, 998, 1034, 1112, 1158, 1240, 1314, 1368, 1411, 1481, 1527, 1559, 1578, 1604, 1658, 2927, and 3063.

6. A Form XXVII atorvastatin calcium a solid state 19 F nuclear magnetic resonance having the following chemical shifts expressed in parts per million: −112.2, −113.0, −117.2.

Assignments (2)
CHANGE OF NAME Recorded Oct 31, 2022
From: UPJOHN US 1 LLC
To: VIATRIS SPECIALTY LLC.
Reel/Frame 061808/0420 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2020
From: WARNER-LAMBERT COMPANY LLC
To: UPJOHN US 1 LLC
Reel/Frame 054293/0956 →